SELLAS Life Sciences (SLS) Cash from Financing Activities (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Cash from Financing Activities of $44.2 million for Q1 2026, up 87.23% year-over-year from $23.6 million in Q1 2025, and up 36.29% quarter-over-quarter from $32.4 million in Q4 2025.
SELLAS Life Sciences (SLS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Cash from Financing Activities for 17 consecutive years, with $44.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 87.23% year-over-year to $44.2 million; the TTM figure through Mar 2026 stood at $106.9 million (up 144.58% YoY), while the FY2025 annual figure was $86.3 million, up 84.56% from the prior year.
- Cash from Financing Activities grew to $44.2 million in Q1 2026 per SLS's latest filing, from $32.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $44.2 million in Q1 2026 and bottomed at -$29000.0 in Q2 2023.
- Historically, Cash from Financing Activities has averaged $13.2 million across 5 years, with a median of $4.2 million in 2025.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 100.13% — and 2025, when it soared 404825.0%.
- SELLAS Life Sciences' Cash from Financing Activities stood at $929000.0 in 2022, then soared by 264.48% to $3.4 million in 2023, then plunged by 99.76% to $8000.0 in 2024, then jumped by 404825.0% to $32.4 million in 2025, then surged by 36.29% to $44.2 million in 2026.
- Business Quant data shows SLS's Cash from Financing Activities at $44.2 million in Q1 2026, $32.4 million in Q4 2025, and $26.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 38.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.83 Mn |
| Jun 30, 2026 | 38.83 Mn |
| Mar 31, 2026 | 44.15 Mn |
| Mar 31, 2026 | 44.15 Mn |
| Dec 31, 2025 | 32.39 Mn |
| Dec 31, 2025 | 32.39 Mn |
| Sep 30, 2025 | 26.09 Mn |
| Sep 30, 2025 | 26.09 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Mar 31, 2025 | 23.58 Mn |
| Mar 31, 2025 | 23.58 Mn |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 19.69 Mn |
| Sep 30, 2024 | 19.69 Mn |
| Jun 30, 2024 | 414,000.00 |
| Jun 30, 2024 | 414,000.00 |
| Mar 31, 2024 | 26.65 Mn |
| Mar 31, 2024 | 26.65 Mn |